文献速递免疫规划传染病防控与疫情报告

10价肺炎链球菌结合疫苗PCV10SII与其他PCV在儿童中的血清效力比较

Seroefficacy of a 10-valent pneumococcal conjugate vaccine (Pneumosil®) compared with other pneumococcal conjugate vaccines in children.
PubMed 文献 · Vaccine · 2026-08-12

该研究基于两项随机试验中716名婴儿的数据,通过比较初免后至加强接种期间血清型特异性IgG升高(血清感染)风险,评估PCV10SII与PCV10GSK及PCV13的血清效力。结果显示PCV10SII与PCV10GSK对共有血清型的血清感染风险无差异,但对6A和19A保护更好;与PCV13相比,PCV10SII对血清型14风险降低65%,对6A和6B风险分别高2.27倍和2.91倍。

要点

  • PCV10SII与PCV10GSK对共有血清型的血清感染风险无差异。
  • PCV10SII对6A和19A的保护优于PCV10GSK。
  • 与PCV13相比,PCV10SII对14型风险降低65%,对6A/6B风险更高。

核心结论

  • PCV10SII对共有血清型的血清效力与PCV10GSK相当,在6A和19A高流行国家可能提供更好覆盖。
  • 评估成本效果时需考虑PCV10SII与PCV13的血清型特异性血清效力差异。

研究设计与样本

  • 基于两项比较PCV10SII与PCV13及PCV10GSK免疫原性的随机试验数据,纳入716名婴儿。
  • 血清感染定义为初免后至加强接种期间血清型特异性IgG任何升高,提示可能定植、亚临床感染或疾病。

主要发现

  • PCV10SII与PCV10GSK对共有血清型的血清感染风险无差异。
  • PCV10SII对6A和19A的保护优于PCV10GSK。
  • 与PCV13相比,PCV10SII对血清型14的血清感染风险降低65%(RR=0.35,95%CI:0.22,0.57)。
  • 与PCV13相比,PCV10SII对6A和6B的血清感染风险分别高2.27倍(95%CI:1.40,3.68)和2.91倍(95%CI:1.84,4.60)。
  • 与PCV13相比,其余血清型的血清感染风险相似。

临床怎么用

  • 在6A和19A疾病高流行国家,PCV10SII可能提供更好的血清型覆盖。
  • 成本效果评估应考虑PCV10SII与PCV13的血清型特异性血清效力差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A new 10-valent pneumococcal conjugate vaccine (PCV10SII) was prequalified by WHO in 2019 for children based on non-inferiority of immunogenicity to PCV13 and PCV10GSK. However, the efficacy of PCV10SII against pneumococcal carriage or disease has not been compared with other PCVs. We compared the risk of seroinfection in PCV10SII with PCV10GSK and PCV13-vaccinated infants. METHODS: Data were available for 716 infants from two randomised trials comparing the immunogenicity of PCV10SII with PCV13 and PCV10GSK. Serotype-specific IgG levels were measured from serum samples collected at four weeks after the primary vaccination series and at the time of booster vaccination. We defined seroinfection as any increase in serotype-specific IgG between post-primary vaccination and the booster dose, indicating likely colonisation, subclinical infection, or disease. We compared the relative risk (RR) of seroinfection between PCVs. RESULTS: There was no difference in the risk of seroinfection between PCV10SII and PCV10GSK for the shared serotypes, but PCV10SII showed better protection against 6A and 19A, not included in PCV10GSK. Compared with PCV13, the risk of seroinfection was 65% lower in PCV10SII for serotype 14 (RR = 0.35, 95% CI: 0.22, 0.57), 2.27-fold (95% CI: 1.40, 3.68) and 2.91-fold (95% CI: 1.84, 4.60) higher for 6A and 6B seroinfection, and similar for the remaining serotypes. CONCLUSION: PCV10SII demonstrated comparable seroefficacy as PCV10GSK against colonisation by serotypes common to both and may offer better coverage in countries with high prevalence of 6A and 19A disease. The serotype-specific differences in seroefficacy between PCV10SII and PCV13 should be considered when evaluating cost effectiveness. Funding Gates Foundation (INV-056261_2023).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Akeju O, Feng S, Clarke E, et al. Seroefficacy of a 10-valent pneumococcal conjugate vaccine (Pneumosil®) compared with other pneumococcal conjugate vaccines in children. Vaccine. 2026. PMID: 42585812. doi:10.1016/j.vaccine.2026.129029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。